Vanda Pharmaceuticals Granted Orphan Designation for Imsidolimab for the Treatment of Generalized Pustular Psoriasis by the European Commission

Rhea-AI Summary

Vanda Pharmaceuticals (Nasdaq: VNDA) reported that the European Commission has granted Orphan Designation to its investigational drug imsidolimab for treating Generalized Pustular Psoriasis (GPP), following a positive opinion from EMA’s Committee for Orphan Medicinal Products.

According to Vanda, this is the first orphan designation in the EU for a GPP treatment. Imsidolimab already holds orphan status in the United States and Japan. EU orphan designation can provide protocol assistance, reduced regulatory fees and post‑approval market exclusivity. Vanda added that an imsidolimab BLA for GPP is under FDA review with a target action date of December 12, 2026.

Positive

• EU Orphan Designation granted for imsidolimab in GPP by the European Commission
• First-ever orphan designation in the EU for a drug to treat GPP
• Imsidolimab orphan designations now in Europe, United States and Japan
• EU orphan status offers protocol assistance, fee reductions and potential market exclusivity
• Imsidolimab BLA for GPP under FDA review with target action date December 12, 2026

Negative

• None.

Market Context

An active S-3 shelf dated February 12, 2026 permits Vanda to offer up to $200,000,000 of securities....

Analysis

An active S-3 shelf dated February 12, 2026 permits Vanda to offer up to $200,000,000 of securities. That financing context sits alongside the designation, with FDA review and its December 12, 2026 target date remaining watch items.

Key Figures

EU prevalence criterion: fewer than 5 in 10,000 people FDA target action date: December 12, 2026

2 metrics

EU prevalence criterion fewer than 5 in 10,000 people European Union orphan designation eligibility

FDA target action date December 12, 2026 imsidolimab BLA for GPP

Historical Context

5 past events · Latest: Aug 05 (Negative)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Aug 05	Q2 earnings report	Negative	+0.5%	Sales declined year over year while net loss widened despite cash runway commentary.
Jul 29	Earnings date notice	Neutral	+2.6%	Company scheduled second-quarter results and its management conference call.
Jul 16	EMA orphan designation	Positive	-0.2%	EMA committee issued a positive opinion recommending orphan designation for imsidolimab.
Jul 15	Marketing partnership announcement	Neutral	-6.8%	NEREUS sponsored Rahal Letterman Lanigan Racing's No. 47 IndyCar entry.
Jul 10	Investor conference appearance	Neutral	-3.9%	Vanda announced participation in a B. Riley Securities summit fireside chat.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent events showed repeated divergence between assigned news sentiment and VNDA's 24-hour price reactions, including the prior EMA orphan-designation announcement.

Key Terms

orphan designation, interleukin-36, il-36 receptor signaling, biologics license application

4 terms

orphan designation regulatory

"has received Orphan Designation from the European Commission"

Orphan designation is a regulatory label granted to a drug or therapy intended to treat a rare disease, which typically affects a small number of patients. It matters to investors because it unlocks incentives—such as development cost reductions, tax credits, priority review and a period of market exclusivity—that improve the commercial and regulatory prospects of a product; think of it as a government-backed head start and safety net for a niche but potentially high-value medicine.

interleukin-36 medical

"dysregulation in the interleukin-36 (IL-36) signaling pathway"

Interleukin-36 is a group of immune signaling proteins that help control inflammation by turning immune responses up or down, like a thermostat for the body’s defense system. It matters to investors because drugs or tests that alter or measure these proteins can become treatments or diagnostics for inflammatory and autoimmune diseases, affecting a biotech or pharmaceutical company’s clinical prospects, regulatory outlook, and potential market value.

il-36 receptor signaling medical

"Imsidolimab inhibits IL-36 receptor signaling"

The IL-36 receptor signaling pathway is a chain of molecular events that starts when IL-36 proteins bind to the IL-36 receptor on immune cells, triggering inflammation and changes in cell behavior. It matters to investors because drugs or diagnostics that modify this pathway can be potential treatments for inflammatory and autoimmune diseases; think of it like a specific fuse and circuit in the body’s inflammatory “wiring” that companies may aim to turn on or off.

biologics license application regulatory

"the imsidolimab Biologics License Application (BLA) for GPP"

A biologics license application is a formal request submitted to regulatory authorities seeking approval to market a new biological medicine, such as vaccines or treatments made from living organisms. It is a comprehensive review process that evaluates the safety, effectiveness, and manufacturing quality of the product. For investors, receiving approval signals that a biological therapy can be sold to the public, potentially leading to revenue growth and market success.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

WASHINGTON, Aug. 24, 2026 /PRNewswire/ -- Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) today announced that its investigational drug imsidolimab has received Orphan Designation from the European Commission, based on the positive opinion received from the European Medicines Agency's (EMA) Committee for Orphan Medicinal Products (COMP), for the treatment of Generalized Pustular Psoriasis (GPP), which is a severe, chronic, and potentially life-threatening inflammatory skin disease driven by dysregulation in the interleukin-36 (IL-36) signaling pathway.¹ The US Food and Drug Administration (FDA) and Japan's Ministry of Health, Labour and Welfare have previously granted Orphan Drug Designation to imsidolimab for the treatment of GPP.

This marks the first time the European Commission has granted orphan designation recognition for a drug to treat GPP in the European Union (EU). GPP is clinically distinct from plaque psoriasis and is characterized by widespread pustular eruptions, systemic inflammation, and serious complications that can lead to increased mortality.^2,3,4 Imsidolimab inhibits IL-36 receptor signaling, addressing the deficiency in the endogenous IL-36 receptor antagonist commonly observed in patients with GPP.

Orphan Designation in the EU is granted by the European Commission following an opinion from EMA's COMP for medicines intended for the diagnosis, prevention, or treatment of life-threatening or chronically debilitating rare conditions. Among other criteria, the condition must affect fewer than 5 in 10,000 people in the EU. Benefits include protocol assistance, reduced regulatory fees, and market exclusivity provisions in the EU following approval.

"The European Commission's Orphan Designation for imsidolimab represents an important milestone for the GPP community and for our efforts to bring this investigational therapy to patients in Europe," said Dr. Mihael H. Polymeropoulos, Vanda's President, CEO and Chairman of the Board. "With orphan designations now received in Europe, the United States and Japan, we remain focused on advancing imsidolimab for patients in these markets who need new treatment options."

This designation follows similar regulatory recognitions in the United States and Japan. Additionally, the imsidolimab Biologics License Application (BLA) for GPP is currently under review by the FDA with a target action date of December 12, 2026.

References

1. Smieszek, S. et al. Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. NEJM Evidence 5, (2026).
2. Ministry of Health Labour and Welfare (MHLW), "Pustular psoriasis (generalized type) (Designated Intractable Disease 37)," Japan Intractable Diseases Information Center. Accessed: Mar. 10, 2026. [Online]. Available: https://www.nanbyou.or.jp/entry/168
3. H. Fujita, R. Iwasaki, S. Tsuboi, Y. Murashiuma, and M. Akiyama, "Regional differences in the prevalence of generalized pustular psoriasis in Japan," J. Dermatol., vol. 51, no. 3, pp. 380–390, Mar. 2024, doi: 10.1111/1346-8138.17089.
4. H. Miyachi et al., "Treatments and outcomes of generalized pustular psoriasis: A cohort of 1516 patients in a nationwide inpatient database in Japan," J. Am. Acad. Dermatol., vol. 86, no. 6, pp. 1266–1274, Jun. 2022, doi: 10.1016/j.jaad.2021.06.008.

About imsidolimab

Imsidolimab is a fully humanized IgG4 monoclonal antibody that inhibits IL-36 receptor signaling and is being developed for GPP, a rare orphan indication. Regulatory and patent exclusivity for imsidolimab is expected to extend into the late 2030s. Vanda holds an exclusive global license for the development and commercialization of imsidolimab.

About Vanda Pharmaceuticals Inc.

Vanda is a leading global biopharmaceutical company focused on the development and commercialization of innovative therapies to address high unmet medical needs and improve the lives of patients. For more on Vanda Pharmaceuticals Inc., please visit www.vandapharma.com and follow us on X @vandapharma.

CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Various statements in this press release, including but not limited to statements regarding the potential benefits associated with EMA approval of an orphan drug, the therapeutic potential of imsidolimab for patients with GPP in the EU, the United States and Japan, and the anticipated timing of the completion of the FDA's review of the imsidolimab BLA are "forward-looking statements" under the securities laws. All statements other than statements of historical fact are statements that could be deemed forward-looking statements. Forward-looking statements are based upon current expectations and assumptions that involve risks, changes in circumstances and uncertainties. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, Vanda's ability to obtain approval of, and to successfully commercialize, imsidolimab in the EU, the United States and Japan for the treatment of patients with GPP, Vanda's ability to satisfy the conditions necessary to receive the benefits associated with EMA approval of an orphan drug, and the FDA's ability to complete its review of, and reach a decision with respect to, the imsidolimab BLA by December 12, 2026. Therefore, no assurance can be given that the results or developments anticipated by Vanda will be realized or, even if substantially realized, that they will have the expected consequences to, or effects on, Vanda. Forward-looking statements in this press release should be evaluated together with the various risks and uncertainties that affect Vanda's business and market, particularly those identified in the "Cautionary Note Regarding Forward-Looking Statements", "Risk Factors" and "Management's Discussion and Analysis of Financial Condition and Results of Operations" sections of Vanda's most recent Annual Report on Form 10-K, as updated by Vanda's subsequent Quarterly Reports on Form 10-Q, Current Reports on Form 8-K and other filings with the U.S. Securities and Exchange Commission, which are available at www.sec.gov.

All written and verbal forward-looking statements attributable to Vanda or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements contained or referred to herein. Vanda cautions investors not to rely too heavily on the forward-looking statements Vanda makes or that are made on its behalf. The information in this press release is provided only as of the date of this press release, and Vanda undertakes no obligation, and specifically declines any obligation, to update or revise publicly any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Contact:
Kevin Moran
Senior Vice President, Chief Financial Officer and Treasurer
Vanda Pharmaceuticals Inc.
202-734-3400
pr@vandapharma.com

Jim Golden / Jack Kelleher / Dan Moore
Collected Strategies
VANDA-CS@collectedstrategies.com

View original content to download multimedia:https://www.prnewswire.com/news-releases/vanda-pharmaceuticals-granted-orphan-designation-for-imsidolimab-for-the-treatment-of-generalized-pustular-psoriasis-by-the-european-commission-302857847.html

SOURCE Vanda Pharmaceuticals Inc.

FAQ

What did the European Commission grant to Vanda Pharmaceuticals (VNDA) for imsidolimab in August 2026?

The European Commission granted Orphan Designation to imsidolimab for treating generalized pustular psoriasis (GPP). According to Vanda, this follows a positive opinion from EMA’s COMP and is the first time a GPP treatment has received orphan designation in the European Union.

Why is EU Orphan Designation for imsidolimab important for Vanda Pharmaceuticals (VNDA) investors?

EU Orphan Designation can provide protocol assistance, reduced regulatory fees and market exclusivity after approval. According to Vanda, this regulatory status supports development of imsidolimab for GPP in Europe and complements existing orphan designations in the United States and Japan.

Is imsidolimab approved for generalized pustular psoriasis and what is the FDA timeline for VNDA?

Imsidolimab is described as an investigational drug and is not yet approved for GPP. According to Vanda, its Biologics License Application for GPP is under FDA review with a target action date of December 12, 2026.

What benefits does EU Orphan Designation provide for imsidolimab in GPP for Vanda (VNDA)?

EU Orphan Designation can offer protocol assistance, reduced regulatory fees and post‑approval market exclusivity. According to Vanda, these benefits apply to medicines for rare, life‑threatening or chronically debilitating conditions affecting fewer than 5 in 10,000 people in the EU.

How rare is generalized pustular psoriasis (GPP) targeted by imsidolimab for Vanda (VNDA)?

Generalized pustular psoriasis is described as a severe, chronic and potentially life‑threatening inflammatory skin disease. According to EU orphan criteria cited by Vanda, qualifying conditions must affect fewer than 5 in 10,000 people in the European Union.

Does imsidolimab already have Orphan Drug Designation outside Europe for Vanda Pharmaceuticals (VNDA)?

Yes, imsidolimab previously received Orphan Drug Designation in the United States and Japan for GPP. According to Vanda, the new European Commission decision means imsidolimab now holds orphan designations across Europe, the United States and Japan for this indication.